96 related articles for article (PubMed ID: 12581495)
1. Mechanisms of immunotherapeutic intervention by anti-CD154 (CD40L) antibody in high-risk corneal transplantation.
Qian Y; Hamrah P; Boisgerault F; Yamagami S; Vora S; Benichou G; Dana MR
J Interferon Cytokine Res; 2002 Dec; 22(12):1217-25. PubMed ID: 12581495
[TBL] [Abstract][Full Text] [Related]
2. Blockade of CD40-CD154 costimulatory pathway promotes survival of allogeneic corneal transplants.
Qian Y; Boisgerault F; Benichou G; Dana MR
Invest Ophthalmol Vis Sci; 2001 Apr; 42(5):987-94. PubMed ID: 11274076
[TBL] [Abstract][Full Text] [Related]
3. Effect of locally administered anti-CD154 (CD40 ligand) monoclonal antibody on survival of allogeneic corneal transplants.
Qian Y; Dana MR
Cornea; 2002 Aug; 21(6):592-7. PubMed ID: 12131037
[TBL] [Abstract][Full Text] [Related]
4. Early ocular chemokine gene expression and leukocyte infiltration after high-risk corneal transplantation.
Yamagami S; Hamrah P; Zhang Q; Liu Y; Huq S; Dana MR
Mol Vis; 2005 Aug; 11():632-40. PubMed ID: 16145544
[TBL] [Abstract][Full Text] [Related]
5. Modulation of costimulation by CD28 and CD154 alters the kinetics and cellular characteristics of corneal allograft rejection.
Ardjomand N; McAlister JC; Rogers NJ; Tan PH; George AJ; Larkin DF
Invest Ophthalmol Vis Sci; 2003 Sep; 44(9):3899-905. PubMed ID: 12939307
[TBL] [Abstract][Full Text] [Related]
6. Deletion of the chemokine receptor CCR1 prolongs corneal allograft survival.
Hamrah P; Yamagami S; Liu Y; Zhang Q; Vora SS; Lu B; Gerard CJ; Dana MR
Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1228-36. PubMed ID: 17325167
[TBL] [Abstract][Full Text] [Related]
7. MHC-matched corneal allograft rejection in an IFN-gamma/IL-17-independent manner in C57BL/6 mice.
Yamada J; Hamuro J; Fukushima A; Ohteki T; Terai K; Iwakura Y; Yagita H; Kinoshita S
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2139-46. PubMed ID: 19136699
[TBL] [Abstract][Full Text] [Related]
8. Costimulatory blockade prevents early rejection, promotes lymphocyte apoptosis, and inhibits the upregulation of intragraft interleukin-6 in an orthotopic liver transplant model in the rat.
Bartlett AS; McCall JL; Ameratunga R; Howden B; Yeong ML; Benjamin CD; Hess D; Peach R; Munn SR
Liver Transpl; 2002 May; 8(5):458-68. PubMed ID: 12004346
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing interleukin-4 prevents transplant arteriosclerosis mediated by indirect pathway T cells under CD40-CD154 costimulation blockade.
Spriewald BM; Ensminger SM; Bushell A; Wood KJ
Transplantation; 2008 Dec; 86(11):1615-21. PubMed ID: 19077898
[TBL] [Abstract][Full Text] [Related]
10. Differential chemokine gene expression in corneal transplant rejection.
Yamagami S; Miyazaki D; Ono SJ; Dana MR
Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):2892-7. PubMed ID: 10549649
[TBL] [Abstract][Full Text] [Related]
11. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation.
Yamagami S; Dana MR; Tsuru T
Cornea; 2002 May; 21(4):405-9. PubMed ID: 11973391
[TBL] [Abstract][Full Text] [Related]
12. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction.
Sano Y; Ksander BR; Streilein JW
Invest Ophthalmol Vis Sci; 1995 Oct; 36(11):2176-85. PubMed ID: 7558710
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
[TBL] [Abstract][Full Text] [Related]
14. Mice with Th2-biased immune systems accept orthotopic corneal allografts placed in "high risk" eyes.
Yamada J; Yoshida M; Taylor AW; Streilein JW
J Immunol; 1999 May; 162(9):5247-55. PubMed ID: 10227999
[TBL] [Abstract][Full Text] [Related]
15. Topical soluble tumor necrosis factor receptor type I suppresses ocular chemokine gene expression and rejection of allogeneic corneal transplants.
Qian Y; Dekaris I; Yamagami S; Dana MR
Arch Ophthalmol; 2000 Dec; 118(12):1666-71. PubMed ID: 11115261
[TBL] [Abstract][Full Text] [Related]
16. Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis.
Howard LM; Ostrovidov S; Smith CE; Dal Canto MC; Miller SD
J Clin Invest; 2002 Jan; 109(2):233-41. PubMed ID: 11805135
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis.
Howard LM; Miga AJ; Vanderlugt CL; Dal Canto MC; Laman JD; Noelle RJ; Miller SD
J Clin Invest; 1999 Jan; 103(2):281-90. PubMed ID: 9916140
[TBL] [Abstract][Full Text] [Related]
18. [CTLA4-Ig prevents corneal allograft rejection in mice].
Shi WY; Xie LX
Zhonghua Yan Ke Za Zhi; 2004 Oct; 40(10):696-700. PubMed ID: 16200862
[TBL] [Abstract][Full Text] [Related]
19. J2 prolongs the corneal allograft survival through inhibition of the CD4+ T cell-mediated response in vivo.
Xiao H; Zhang H; Yu ZY; Zhang L; Yu M; Huang YF; Li S; Shen BF; Li Y
Transpl Immunol; 2007 Nov; 18(2):130-7. PubMed ID: 18005857
[TBL] [Abstract][Full Text] [Related]
20. T-cell mediated responses in a murine model of orthotopic corneal transplantation.
Joo CK; Pepose JS; Stuart PM
Invest Ophthalmol Vis Sci; 1995 Jul; 36(8):1530-40. PubMed ID: 7601633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
